Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. - Johnson JS; Miller JW; Hatoum F; Schell MJ; Yu X; Roman Souza G; Mizelle S; Gullapalli K; Fazili A; Jain R; Chatzkel J; Cen L; et al. (Nature communications, 2026)